Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446237 · ClinicalTrials.gov registry record · NA
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
A NA study of Acne Vulgaris, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 9
- Study locations
NCT01446237 is a NA study of Acne Vulgaris that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 125 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (54% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT01446237, a NA study of Acne Vulgaris, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent Salicylic Acid (SA) 0.5% in the treatment of moderate to severe acne. Subjects with moderate or severe acne will be asked to apply the commercially available, over-the-counter products Foam Deep Cleanser (2.5% BPO), Foam Advanced Acne Treatment (2.5% BPO), and Foam Rejuvenating Toner (0.5% SA) daily for 12 weeks. No control group or reference treatment will be included.
Conditions Studied
Interventions
- OTHER acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Study Locations (9)
New Jersey
- GSK Investigational Site - Belleville
- GSK Investigational Site - Montclair
California
- GSK Investigational Site - Fremont
Kentucky
- GSK Investigational Site - Louisville
Maryland
- GSK Investigational Site - Rockville
New York
- GSK Investigational Site - Stony Brook
North Carolina
- GSK Investigational Site - High Point
Tennessee
- GSK Investigational Site - Knoxville
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2011-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01446237
The ClinicalTrials.gov registry entry for NCT01446237 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (54% lower). The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5% is the first listed.
NCT01446237 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New Jersey, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01446237 about?
NCT01446237 is a clinical study titled "U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne". This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent Salicylic Acid (SA) 0.5% in the treatment of moderate to severe acne. Subjects with moderate or severe acne will be asked to app...
What is the current status of trial NCT01446237?
This trial is currently completed. It is a NA study. The enrollment target is 125 participants. The study started on 2011-06-01. Estimated completion is 2011-12-15.
What conditions does trial NCT01446237 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01446237?
The interventions under investigation include: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5% (OTHER).
Who is sponsoring clinical trial NCT01446237?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01446237 being conducted?
This trial has 9 study locations across California, Kentucky, Maryland, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Laser Treatment of Moderate to Severe Acne Vulgaris
ACTIVE NOT RECRUITING · NA
-
A Post Market Device Study for the Treatment of Acne
ACTIVE NOT RECRUITING · NA
-
A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin
COMPLETED · NA
-
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
COMPLETED · NA
-
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
COMPLETED · NA
-
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.